I ntroduction: Hypertension represents an important public health problem. Effective treatment of hypertension is imperative for primary care. Goal: The goal of this study was to examine the efficacy of Valsartan in the treatment of hypertension with emphasis on the overall efficacy in reduction of systolic and diastolic blood pressure in a sample of 738 patients. Material and methods: The study lasted for 12 months (from January 1, 2012 until December 31, 2012 year) and conducted in 18 public health institutions in B&H. Parallel follow up of Valsartan antihypertensive effect through repeated measurements every three months was conducted. Results and discussion: Our results indicate that both systolic and diastolic blood pressure decreased significantly after 12 weeks of Valsartan treatment. Analysis of adverse effects did not showed statistical significance of side effects for total sample. Statistical analysis by Yates chi-square did not show the presence of statistically significant differences in adverse effects by gender. Conclusion: We conclude that Val or Val plus are effective and safe antihypertensive drugs for the treatment of mild to moderate hypertension.
INTRODUCTION
Hypertension is the most important chronic health problem. It is estimated that hypertension affects approximately one billion people and that this number will increase by 60% until the year 2025. Hypertension is the first risk factor for cerebrovascular accidents and cardiovascular disorders. The degree of hypertension based on blood pressure as continuous variable that changes from minute to minute, depending on the patient's mental and physical condition and environmental factors. Hypertension represents a challenge for family physicians because the need of early detection and treatment, but also to achieve blood pressure control. According to the World Health Organization and the International Society of Hypertension, it is defined as elevated blood pressure when the level of systolic blood pressure is 140 mmHg (18.7 kPa) or more and/or the level of diastolic blood pressure is 90 mmHg (12.0 kPa) or more, in repeated measurements. It can occur as isolated systolic or diastolic hypertension but most often both pressures are elevated. Due to the changes that occur in large arteries by aging, systolic blood pressure after the fifty year is increasing with each year of life by about 2 mmHg and diastolic blood pressure by 0.5 to 1 mmHg. Men have higher levels of blood pressure than women until age 60. Later, this difference disappears so in the older age women have higher values of blood pressure and higher prevalence of hypertension. Lowering blood pressure for 9/5 mmHg reduces the risk of stroke by 30% and the risk of ischemic diseases by 20% (1, 2) .
The majority of patients with hypertension have essential or primary hypertension, which have unknown cause and in which the initially high blood pressure is the only manifestations of disease. In other patients hypertension is caused by disease of some other organ and therefore is called secondary hypertension. The degree of clinical severity of hypertension is estimated on the basis of systolic blood pressure and current changes in other organ systems (1,3).
According to the causes, hypertension can be:
• Essential;
• Renal hypertension;
• Endocrine hypertension;
• Cardiovascular hypertension;
• Neurogenic hypertension; • Hypertension in pregnancy or hypertension gravitas; • Hypertension induced by drugs or iatrogenic hypertension. Effect of hypertension manifests in the development of left ventricular hypertrophy due to the increased pressure load and acceleration of atherosclerosis in the coronary arteries, as well as in the arteries of the brain, heart, kidneys and lower limbs (3, 4).
Most hypertensive patients have no symptoms and such persons are detected only by physical examination.
Symptoms that indicate hypertension
Valsartan in the Treatment of hypertension to a doctor can be divided into three groups and relate to:
• Increase of blood pressure only;
• Hypertensive angiopathy;
• Primary disease in the case of secondary hypertension. Clear family history of hypertension with information about the occasional increase of blood pressure in the past goes in favor of the diagnosis of essential hypertension. Secondary hypertension mostly occurs before 35 or after 55 years of age. Data on the use of corticosteroids or estrogen is obviously very significant. History of recurrent urinary tract infections indicates chronic pyelonephritis, although this situation develops and asymptomatic, nocturia and polydipsia indicate renal or endocrine disease and lumbar trauma or episodes of acute pain in the groin can be a guideline to kidney damage. Specifying weight gain is compatible with Cushing's syndrome and weight loss indicates pheochromocytoma (2, 4, 5, 6) .
The clinical evaluation of patients with hypertension should:
• Confirm the presence of hypertension; • Determine the presence and extent of hypertension effects on the other organs; • Identify cardiovascular risk factors and other existing diseases that affect prognosis and treatment; • Exclude or confirm the causes of secondary hypertension (2, 5, 6) . Therapeutic approach to the individual patient with hypertension depends on associated risk factors that favor the development of cardiovascular disease, the existence of cardiovascular disease and target organ damage.
Essential hypertension cannot be cured, but proper treatment can significantly influence its course. Changing the lifestyle is an important component in the treatment of essential hypertension. Correction of body weight, regular physical activity, diet with limited intake of salt (<6g per day), saturated fat and alcohol and smoking cessation can significantly reduce blood pressure and increase the effectiveness of antihypertensive therapy.
Treatment with antihypertensive medications is indicated if by lifestyle changes the blood pressure cannot be maintained in the desired range.
• Diuretics (thiazides);
• Beta-blockers;
• ACE inhibitors;
• Angiotensin II receptor blockers;
• Calcium channel blockers. All these medications can be used as first-line medications for the treatment of hypertension. Antihypertensive effect of thiazides is reflected in the reduction of plasma volume and betablockers in reducing sympathetic activity and negative inotropic effect on the myocardium.
ACE inhibitors and angiotensin II receptor blockers are vasodilators because by indirect effect on certain areas of the renin-angiotensin system reduces peripheral vascular resistance. ACE inhibitors prevent conversion of angiotensin I to angiotensin II, and angiotensin receptor blockers block the binding of angiotensin II to angiotensin receptors.
Calcium channel blockers are powerful vasodilators, because they directly reduce tension of blood vessels smooth muscles and thereby reduce peripheral vascular resistance. Treatment of secondary hypertension is directed at the cause (7, 8, 9, 10) .
Valsartan is competitive angiotensin II receptor antagonist, selective for their AT1 subtype. Specific selective blockade of AT1 receptors and consecutive antagonizing of all the effects not only of angiotensin II, but also other components of the renin-angiotensinaldosterone system is essential effect of valsartan from which derive all of its pharmacodynamics and therapeutic effects.
It is used as monotherapy or in combination with HCTZ for all types of renovascular and essential hypertension.
Valsartan is not metabolized in a way that it produces active metabolite, it is effective for 24 hours and is taken once a day.
For the majority of patients after the use of single oral dose antihypertensive activity occurs within two hours. The greatest reduction in blood pressure with any dose is achieved within 2-4 weeks and maintained during longterm treatment. Co-administration with hydrochlorothiazide produces a considerable further reduction in blood pressure.
In patients with congestive heart failure it improves hemodynamics, including pulmonary capillary wedge pressure, pulmonary artery diastolic pressure and systolic blood pressure, systemic vascular resistance and cardiac stroke volume. In clinical studies it was shown that Valsartan can help reduce the risk of heart failure-patients treated with Valsartan showed significant improvement in signs and symptoms of heart failure including dyspnea, fatigue, edema, compared to placebo.
Valsartan is used to treat hypertension and congestive heart failure. Therapeutic doses ranging from 80 to 320 mg.
Pregnant women should not use Valsartan, while special caution is needed in patients who are receiving high doses of diuretics as symptomatic hypotension may occur. Also, caution is needed in patients with liver and kidney damage. Possible side effects are usually dizziness and headache (7, 8, 9, 10, 11).
ReSeARCH GOALS
To evaluate patients suffering from hypertension who were treated with Valsartan (Val or Val plus), in one of the 18 medical institutions in Bosnia and Herzegovina, with the emphasis on the effectiveness of antihypertensive effect of Valsartan from pharmaceutical company Farmavita.
Identify mean systolic blood pressure in the study group of patients by measuring blood pressure during the study time period: every three months (measured once a month).
Identify the differences between the patients examined in our study in relation to gender, age, age groups.
Provide a cross section evaluation of the Valsartan side effects.
MATeRIAL AND MeTHODS
Data used in our study were obtained from the studies and analyzes conducted in 18 health facilities in the territory of B&H. This study included 738 patients who underwent three consecutive medical examinations after they had been on Valsartan therapy. Patients treated in our study completed three examinations in three months: one review a month. Inclusion criterion was hypertension treated with Valsartan.
Valsartan which we used in the study is a manufactured by Farmavita.
Each doctor treated a group of patients from 20 to 50 patients by treating doctor. All doctors keep track of hypertension in a specially designed table on the basis of which they drafted the report. After collecting the data are transformed into the same group study that we presented in tables and figures.
Needed data for monitoring the effectiveness of Valsartan (Val and Val plus) are collected on the basis of medical examinations and notes:
• Anamnesis and previous status.
• Measuring the blood pressure during first, second and third examination.
• Keeping record on side effects during the three months.
• Laboratory tests.
• Diagnostic tests.
Study results are presented in tables and figures by number of cases, percentage and mean with standard deviation and range. Analysis of the statistical significance of the differences is conducted by Pearson and Yates chi-square test and one-way analysis of variance (ANOVA). The results of all these tests with p <0.05 or 95% confidence level were considered statistically significant. Analysis was conducted using the statistical package IBM SPSS Statistics v19.0 (Chicago, Illinois, USA).
ReSULTS
Results are presented tables 1-4 and figures 1-2. Review of the gender structure of the sample indicated that women were slightly more represented with 396 or 53.7% of the respondents in relation to men with 342 or 46.3%.
Analysis of age distribution shows that the majority of respondents were in the older age groups (over 50 years) and that statistically significant difference by chi-square test is recorded in relation to gender (p> 0.05). Larger number of patients has been subjected to the treatment of hypertension for the first time (421 or 57.0%) compared to those who had previously treated hypertension (317 or 43.0%). Analysis of the average blood pressure during the initial examination, the first and second follow-up shows a linear decrease in both systolic and diastolic blood pressure.
It is noticeable that the Valsartan caused side effects in 7.6% of patients in the total sample (N = 738), while the most frequent was hypotension (2.8%), followed by dizziness (1.6%), fatigue in 1.1% and other side effects in less than 1% of patients.
Analysis of adverse events by gender shows that the higher total number is recorded among women as well as hypotension, dizziness, fatigue, nausea and diarrhea, while dizziness, headache and abdominal pain were more often reported by men. Given the small number of side effects statistical analysis using Yates chi-square showed the presence of statistically significant differences in adverse events by gender (χ2=8.737; p=0.2721).
DISCUSSION
In our research, we had 738 patients. Review of the gender structure of the sample indicated that women were slightly more represented with 396 or 53.7% of the respondents in relation to men with 342 or 46.3%. Analysis of age distribution shows that the majority of respondents were in the older age groups (over 50 years) without statistically significant difference by chi-square test in relation to gender (p>0.05). Analysis of average blood pressure during the initial examination, the first and second follow-up showed a linear decrease and statistically significant difference between the groups according to the results of analysis of variance (ANOVA) for both systolic and diastolic blood pressure. Majority of patients have been subjected to the treatment of hypertension for the first time (421 or 57.0%) compared to those who had previously treated hypertension (317 or 43.0%).
Valsartan is non-peptide ARB that selectively blocks binding of angiotensin II to the angiotensin II type 1. Many clinical studies have proven the efficacy, tolerability and safety of Valsartan in reducing BP in different groups of patients and in improving CV outcomes, as well as outcomes of chronic kidney disease. Our results are comparable to the results by Mallion and associates (12) . In several studies they evaluated the efficacy and safety of Valsartan. Reduction in systolic and diastolic blood pressure was clinically and statistically significant and the changes in systolic blood pressure were generally higher than the diastolic. Our results show a linear reduction of both systolic and diastolic BP in relation to this study, we can explain by selective sampling of our subjects according to the inclusion crite- Table 4 . Review of average BP by treatment duration ria (13, 14) . In a series of large-scale clinical trials is established the value of Valsartan in reducing cardiovascular complications and mortality in high-risk patients. Study of Val-HeFT and VAL-IANT demonstrated that the cardiovascular benefit of valsartan is comparable to or better than angiotensin-converting enzyme (ACE) inhibitors and other antihypertensive agents and with better tolerability. We did not compare these results with our study because our goal was not the prevention of cardiovascular complications.
In the future, we will follow the patients from our study, while special emphasis will be given to the cardiovascular complications of patients treated with Valsartan and compared with patients who are not treated or treated by other antihypertensive medications. Most frequent side effect of ACE group, which Valsartan does not cause, a dry cough that occurs in 5% to 35% of patients and does not depend on the dose of the medication. The incidence of cough depends on the applied representative groups, and so for example, Amir et al. 2005 found that is the most common when taking Enalapril (17.3%), followed by Fosinopril (14.7%), Perindopril and Quinapril (14.3%), Lisinopril (12.5%) and Ramipril (8.3%). Within the side effects we did not have any patient with these symptoms which represents a significant advantage of Valsartan in relation to this group of drugs when it comes to the foregoing side effects (15, 16, 17) . Initial blood pressure was measured at the first visit and averaged 152 mmHg for systolic blood pressure and 98 mmHg for diastolic blood pressure. After one month of treatment with Valsartan (Val or Val plus) systolic blood pressure was reduced to an average of 143 mmHg and diastolic pressure to 91 mmHg. The reduction was also observed with the third visit, when the average systolic blood pressure was 132 mmHg and diastolic pressure 84 mmHg. Total reduction of blood pressure has averaged 20 mmHg for systolic and 14 mmHg for diastolic, which is consistent with previously published results. During the treatment a total of 56 adverse events occurred in 56 patients out of 738 and were similar to those on which reported Bisvvas et al. (18) . Most often was hypotension (2.8%), followed by dizziness (1.6%), fatigue in 1.1% and other adverse effects in less than 1% of patients. Above side effects are statistically not significant. Farmavita Valsartan and its fixed dose combination with hydrochlorothiazide (Val and Val Plus) are so valuable therapy for the area of internal medicine. A study of this agent has confirmed the effectiveness of the treatment of hypertension.
CONCLUSIONS
The study was conducted on 738 patients at 18 medical institutions during 2012. Criteria for inclusion in the Valsartan treatment was newly discovered hypertension, hypertension which would not respond to prior therapy or could not be continued due to adverse effects. Our results indicate that both systolic and diastolic blood pressure decreased significantly after 12 weeks of treatment with Valsartan. Analysis of adverse events did not showed statistically significant side effects for the total sample. Statistical analysis using Yates chi-square showed the presence of statistically significant differences in adverse events by gender. Val or Val plus is an effective and safe antihypertensive drug for the treatment of mild to moderate hypertension. It is noticeable that the Valsartan caused side effects in 7.6% of patients in the total sample (N = 738), while the most frequent was hypotension (2.8%), followed by dizziness (1.6%), fatigue in 1.1% and other side effects in less than 1% of patients. Analysis of adverse events by gender shows that the higher total number is recorded among women as well as hypotension, dizziness, fatigue, nausea and diarrhea, while dizziness, headache and abdominal pain were more often reported by men. Given the small number of side effects statistical analysis using Yates chi-square showed the presence of statistically significant differences in adverse events by gender (χ2=8.737; p=0.2721).
DISCUSSION
Valsartan is non-peptide ARB that selectively blocks binding of angiotensin II to the angiotensin II type 1. Many clinical studies have proven the efficacy, tolerability and safety of Valsartan in reducing BP in different groups of patients and in improving CV outcomes, as well as outcomes of chronic kidney disease. Our results are comparable to the results by Mallion and associates (12) . In several studies they evaluated the efficacy and safety of Valsartan. Reduction in systolic and diastolic blood pressure was clinically and statistically significant and the changes in systolic blood pressure were generally higher than the diastolic. Our results show a linear reduction of both systolic and diastolic BP in relation to this study, we can explain by selective sampling of our subjects according to the 
